Immunomedics Inc. (IMMU)

HEALTH CARE: PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

300 AMERICAN RD MORRIS PLAINS, NJ 07950

Immunomedics Inc. develops, manufactures and markets monoclonal antibody-based products for detection and treatment of cancer and other diseases. Focuses on therapeutic antibodies designed to carry radioisotopes, chemotherapeutic agents, toxins and other substances to a specific disease site or organ system.

Data as of 2019-12-02 12:49:09 -0500
Market Cap3.631 Billion Shares Outstanding193.354 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-1.864
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low21.23 / 11.55 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from IMMU instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Immunomedics Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding IMMU (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMMU BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ISLAM KHALID

  • Director
 No longer subject to file 2020-10-23 1

HUTT PETER BARTON

  • Director
 No longer subject to file 2020-10-23 1

CANUTE SCOTT A

  • Director
 No longer subject to file 2020-10-23 1

AGHAZADEH BEHZAD

AVORO CAPITAL ADVISORS LLC

  • Director
  • 10% Owner
  • SEE REMARKSSEE REMARKS
 No longer subject to file 2020-10-23 1

DELANEY BRENDAN CHIEF COMMERCIAL OFFICER

  • Officer
 No longer subject to file 2020-10-23 1

MALIK USAMA CHIEF FIN. & BUSINESS OFFICER

  • Officer
 No longer subject to file 2020-10-23 1

FRICKER WILLIAM PRINCIPAL ACCOUNTING OFFICER

  • Officer
 No longer subject to file 2020-10-23 1

FREEDBERG JARED GEN. COUNSEL & CORP. SECRETARY

  • Officer
 No longer subject to file 2020-10-23 1

ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER

  • Officer
 No longer subject to file 2020-10-23 1

BAUM CHARLES M

  • Director
 No longer subject to file 2020-10-23 1

BALL BRYAN CHIEF QUALITY OFFICER

  • Officer
 No longer subject to file 2020-10-23 1

DUNCAN BARBARA GAYLE

  • Director
 No longer subject to file 2020-10-23 4

ITRI LORETTTA M CHIEF MEDICAL OFFICER

  • Officer
 No longer subject to file 2020-10-23 1

AZELBY ROBERT

  • Director
 No longer subject to file 2020-10-23 1

SEMERJIAN HAROUT PRESIDENT AND CEO

  • Officer
  • Director
 0 2020-04-16 0

ROSENBERG MORRIS CHIEF TECHNOLOGY OFFICER

  • Officer
 0 2019-09-06 0

IANNONE ROBERT CHIEF MEDICAL OFFICER

  • Officer
 0 2019-03-14 0

PEHL MICHAEL F. PRESIDENT AND CEO

  • Officer
 0 2018-09-14 0

GOLDENBERG DAVID M

  • Director
 7,387,537 2018-02-28 0

MARKISON BRIAN A

  • Director
 90,788 2017-11-20 0

AGHAZADEH BEHZAD

  • Director
  • 10% Owner
  • SEE REMARKS
 16,064,461 2017-11-14 1

VENBIO SELECT ADVISOR LLC

  • Director
  • 10% Owner
  • SEE REMARKS
 16,064,461 2017-11-14 0

GOLDENBERG CYNTHIA L

  • Director
 5,906,233 2017-08-31 0

GARONE MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
 0 2017-07-03 0

STARK DON C

  • Director
 No longer subject to file 2017-06-30 0

ARYEH JASON

  • Director
 0 2017-01-08 0

FORRESTER ROBERT

  • Director
 0 2017-01-08 0

COX GEOFFREY F

  • Director
 0 2017-01-08 0

OLIVER BOB

  • Director
 0 2017-01-08 0

PAETZOLD MARY E

  • Director
 78,325 2016-12-02 0

KIRSCH ARTHUR S

  • Director
 0 2015-12-02 0

SHERMAN RICHARD L.

  • Director
 No longer subject to file 2015-12-01 0

PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER

  • Officer
 29,706 2015-08-20 0

COLEMAN MORTON

  • Director
 No longer subject to file 2013-12-04 0

LOCASTRO MARCELLA

  • Director
 No longer subject to file 2013-12-04 0

GORMAN GERARD G SVP, FIN. , AND CFO

  • Officer
 0 2013-08-16 0

ZUERBLIS KENNETH J

  • Director
 9,167 2011-12-07 0

WOLYNIC EDWARD T

  • Director
 6,667 2009-12-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund IMMU -4999.0 shares, $-105778.84 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund IMMU -4122.0 shares, $-87221.52 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund IMMU -27324.0 shares, $-362316.24 2019-09-30 N-PORT
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund IMMU -73.0 shares, $-6207.19 2020-09-30 N-PORT
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund IMMU -83315.0 shares, $-1104756.9 2019-09-30 N-PORT
Trust for Professional Managers- Convergence Market Neutral Fund IMMU -1592.0 shares, $-70939.52 2020-08-31 N-PORT
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund IMMU -50.0 shares, $-663.0 2019-09-30 N-PORT

Elevate your investments